March 22nd 2023
Patritumab deruxtecan continues to yield positive efficacy in 2 early phase trials assessing the agent in patients with metastatic non–small cell lung cancer and breast cancer.
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Trekking Through the Latest Updates for ROS1-Targeted Therapies
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC
Navigating the Latest Data on NTRK-Targeted Therapies
Community Practice Connections™: 17th Annual New York Lung Cancers Symposium
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
Show Me Your Care Plan™: Monitoring and Managing Patients With EGFR Exon20 Insertion+ NSCLC
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
Advancing Precision Care Through Biomarker-Driven Therapy: CEACAM5 as a Therapeutic Target in NSCLC
Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer
Medical Crossfire: How Should We Leverage Multidisciplinary Lung Cancer Care Teams in Managing Earlier Forms of NSCLC... When the Goal Is Cure?
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC
Expert Illustrations & Commentaries™: Exploring the Clinical Rationale for Antagonizing Inflammatory IL-1-beta Signaling in NSCLC
Onco-Nurse Academy™: Exploring an Advent of Targeted Therapies Across Advanced NSCLC Care and Strategies for Managing Adverse Events Associated With Treatment
Patient, Provider, and Caregiver Connection™: Shedding a Light on the Patient Journey with KRAS Mutated Lung Cancer
Clinical Vignettes®: Multidisciplinary Discussions on the Application of Novel EGFR Exon 20 Targeted Regimens for NSCLC Management
Expert Illustrations & Commentaries™: Exploring the Role of Novel Antibody-Drug Conjugates in Advanced NSCLC
Advances In™ NSCLC: Exploring CEACAM5 As A New Therapeutic Target
Community Practice Connections™: Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!
Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care
Advances In™: The Role of NRG1 Fusions Across Tumor Types
Medical Crossfire®: Leveraging EGFR Mutation Profiles to Personalize Therapeutic Decisions in Resected and Metastatic NSCLC Settings
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!
Tolerable Phase 2 Dose of Mobocertinib in Japanese Patients With NSCLC Consistent With Global Maximum-Tolerated DoseSeptember 17th 2021
Results of a phase 1/2 trial revealed the recommended phase 2 and maximum-tolerated dose of mobocertinib in Japanese patients with non–small cell lung cancer.
Mobocertinib Demonstrates Clinically Meaningful Activity Compared With Real-World Data in Advanced EGFR Exon 20 Insertion+ NSCLCSeptember 16th 2021
For patients with advanced EGFR Exon 20 Insertion–positive non–small cell lung cancer, mobocertinib appears to yield clinically meaningful activity compared with real-world data.
Alexander Spira, MD, PhD, Discusses Safety and Efficacy of Mobocertinib in EGFR ex20ins+ NSCLC Following Prior EGFR TKIsSeptember 14th 2021
CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about clinical benefits of using mobocertinib in patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer.
DFS Benefit Noted Across Patient Subgroups for Adjuvant Atezolizumab in Early-Stage NSCLCSeptember 12th 2021
Adjuvant atezolizumab led to disease-free survival benefit in patients with early-stage non–small cell lung cancer, including most patient subgroups, in the phase 3 IMpower010 trial.
Patients With ALK+ NSCLC Not Suitable for Crizotinib Benefit from Sequential ALK-Inhibitor TherapySeptember 11th 2021
Patients with non–small cell lung cancer harboring ALK mutations who were not suitable for crizotinib therapy, either due to resistance or intolerance, showed benefit with sequential crizotinib and alectinib.
Atezolizumab Combo Demonstrates Favorable Efficacy and Safety Data for NSCLC with Untreated Brain MetastasesSeptember 10th 2021
Patients with non-small cell lung cancer with brain metastases experienced a favorable safety profile along with efficacy results when treated with atezolizumab plus chemotherapy.
Durvalumab and Chemotherapy, Plus or Minus Tremelimumab Yields Survival Benefit in Frontline Treatment of Advanced NSCLCSeptember 9th 2021
The phase 3 POSEIDON trial indicated that patients with metastatic non–small cell lung cancer who were treated with first-line durvalumab and chemotherapy with or without tremelimumab experienced a statistically significant survival benefit.
Clinical Activity Observed With Mobocertinib for Advanced EGFR Exon 20 Insertion+ NSCLC With or Without Prior ImmunotherapySeptember 9th 2021
Previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer saw clinical activity with mobocertinib regardless of prior PD-1/PD-L1 inhibitor history.
Intracranial Activity Seen With Sotorasib for KRAS G12C–Mutated NSCLC Brain MetastasesSeptember 8th 2021
For patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases who were previously treated with either radiation or surgery, robust anticancer activity was observed with intracranial complete responses and continued intracranial stabilization with sotorasib.
Pelcitoclax Plus Osimertinib Shows Promise in Patients With EGFR TKI–Resistant NSCLCSeptember 8th 2021
Patients with EGFR-positive non–small cell lung cancer whose disease is not suitable for standard EGFR TKI monotherapy had promising responses and experienced few dose-limiting toxicities with pelcitoclax plus osimertinib.
PFS Benefit Observed With Tislelizumab Plus Chemotherapy for Advanced Squamous NSCLCSeptember 8th 2021
Patients with stage IIIB and stage IV advanced squamous non–small cell lung cancer experienced a clinically significant improvement in progression-free survival with tislelizumab plus chemotherapy in the first-line setting compared with standard of care chemotherapy.
Mobocertinib Improves PROs in Previously Treated EGFR Exon 20+ NSCLCSeptember 8th 2021
In a phase 1/2 trial, the selective targeting of EGFR exon 20 insertion mutations with mobocertinib in patients with previously treated non–small cell lung cancer resulted in superior patient-reported outcomes.
Adding Metformin to Concurrent Radiotherapy Does Not Improve Survival in Locally Advanced Non–Small Cell Lung CancerSeptember 7th 2021
Findings from the phase 2 NRG-LU001 trial indicated that the addition of metformin to radiotherapy did not improve survival outcomes in patients with non–small cell lung cancer.
Encouraging Overall Response Rate Reported With Domvanalimab-Combinations in Non-Small Cell Lung CancerSeptember 3rd 2021
A 3-arm randomized study indicated that domvanalimab-based combinations yielded a promising overall response rate for patients with metastatic non–small cell lung cancer with a PD-L1 status of 50% or more.
Hypofractionated Image-Guided Versus Conventionally Fractionated Radiotherapy Shows No Treatment Advantage in NSCLC With Poor Performance StatusAugust 29th 2021
The use of hypofractionated image-guide radiotherapy was not found to improve overall survival for patients with non–small cell lung cancer and poor performance status versus conventional fractionated radiation techniques.
Higher Risk of Recurrence, Worse Survival Related to Delayed Surgery in Veterans With Stage I NSCLCAugust 24th 2021
Veterans diagnosed with stage I non–small cell lung cancer who have experienced delays in their surgical treatment over the past 12 weeks are at a higher risk of negative disease outcomes compared with those receiving surgery immediately after diagnosis.
Impact of Residential Segregation and Structural Racism on Outcomes and Treatment of Black Patients With NSCLCAugust 20th 2021
Black patients with non–small cell lung cancer were more likely to be diagnosed at advanced stages of disease, less likely to receive surgery in early stages, and had increased cancer mortality rates than White patients.
Metformin With Chemoradiotherapy Is Not Recommended for the Treatment of Locally Advanced Non–Small Cell Lung CancerAugust 16th 2021
Investigators advise against the use metformin in addition to chemoradiotherapy for patients with locally advanced non–small cell lung cancer due to progression-free survival and overall survival was not substantial.
Addition of Plinabulin to Docetaxel Produced Positive Outcomes in Second- and Third-Line EGFR Wild-Type NSCLCAugust 4th 2021
Patients with EGFR wild-type non–small cell lung cancer experienced a survival benefit with the addition of plinabulin to docetaxel in the second- and third-line settings.